DOCSLIB.ORG

Toward Noninvasive Quantification of Brain Radioligand Binding by Combining Electronic Health 1273

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toward Noninvasive Quantification of Brain Radioligand Binding by Combining Electronic Health 1273 IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS, VOL. 19, NO. 4, JULY 2015 1271 Toward Noninvasive Quantification of Brain Radioligand Binding by Combining Electronic Health Records and Dynamic PET Imaging Data Arthur Mikhno, Francesca Zanderigo, R. Todd Ogden, J. John Mann, Elsa D. Angelini, Andrew F. Laine, and Ramin V. Parsey Abstract—Quantitative analysis of positron emission tomogra- analysis of PET data requires both the arterial input function phy (PET) brain imaging data requires a metabolite-corrected ar- (AIF) that describes the amount of radioligand available for dif- terial input function (AIF) for estimation of distribution volume fusion into the brain, and the tissue time-activity curves (TACs) and related outcome measures. Collecting arterial blood samples adds risk, cost, measurement error, and patient discomfort to PET derived from dynamic PET images. Kinetic modeling is then studies. Minimally invasive AIF estimation is possible with simul- performed to estimate important outcome measures of radioli- taneous estimation (SIME), but at least one arterial blood sample is gand distribution and binding [1]. To measure the AIF, typically necessary. In this study, we describe a noninvasive SIME (nSIME) a catheter is inserted into the radial artery at a subjects’ wrist approach that utilizes a pharmacokinetic input function model to sample blood for the duration of the PET scan. After cen- and constraints derived from machine learning applied to an elec- tronic health record database consisting of “long tail” data (digital trifugation, the total radioactivity concentration of radioligand records, paper charts, and handwritten notes) that were collected in the arterial plasma (TP) is measured in each blood sample. If ancillary to the PET studies. We evaluated the performance of the body metabolizes the radioligand, the parent fraction (PF) nSIME on 95 [11C]DASB PET scans that had measured AIFs. The of unmetabolized radioligand in the plasma is assayed from a results indicate that nSIME is a promising alternative to invasive subset of the blood samples. After fitting PF using a metabolite AIF measurement. The general framework presented here may be × expanded to other metabolized radioligands, potentially enabling model, the input function is calculated as AIF : y =TP PF, quantitative analysis of PET studies without blood sampling. A which reflects the concentration y of radioligand in plasma that glossary of technical abbreviations is provided at the end of this is available to enter the target tissue. paper. Utilizing the AIF and the TACs, PET imaging can be used Index Terms—Arterial input function (AIF), electronic health to estimate outcome measures related to the “binding poten- record (EHR), positron emission tomography (PET) imaging. tial” of a radioligand to its target. In particular, one estimate of binding potential BPF is defined as: BPF = Bavail/KD = I. INTRODUCTION (VT − VND)/fP , where Bavail is the concentration of available OSITRON emission tomography (PET) uses radioactively receptors, 1/KD is the radioligand affinity to the target, VT P tagged probes (radioligands) for the in vivo quantification is the radioligand “volume of distribution” or volume of ra- of blood flow, metabolism, protein distribution, gene expres- dioligand in tissue relative to plasma, VND is the radioligand sion, and drug target occupancy in the brain. Fully quantitative “volume of distribution” in a tissue devoid of the target (i.e., fraction of binding not specific to the target of interest), and fP Manuscript received October 15, 2014; revised January 5, 2015 and March is the free fraction of the radioligand in plasma. VT and VND 6, 2015; accepted March 14, 2015. Date of publication March 24, 2015; date of are estimated from kinetic modeling of the region TACs and the current version July 23, 2015. This work was supported by the National Insti- tute of Mental Health (NIMH) F31 Predoctoral Fellowship (1F31MH095338) AIF, while fP can be assayed in additional blood samples col- and NIMH Grants MH040695 and MH062185, and the National Center for lected prior to radioligand injection. When fP is not available, Advancing Translational Sciences, National Institutes of Health, Grant TL1 or cannot be measured reliably, two other variants binding po- TR000082. − A. Mikhno, E. D. Angelini, and A. F. Laine are with the Department of tential can be calculated: BPP = fP BPF =(VT VND) and Biomedical Engineering, Columbia University, New York, NY 10027 USA BPND = f NDBPF =(V T − V ND)/V ND, where fND is the (e-mail: [email protected]; [email protected]; AL418@columbia. free fraction of the radioligand in a tissue devoid of target. edu). F. Zanderigo is with the Department of Psychiatry, Columbia Univer- Thus, quantification of PET data requires arterial blood sam- sity and the Division of Molecular Imaging and Neuropathology, New pling to estimate the AIF and to calculate the outcome measures York Psychiatric Institute, New York, NY 10021 USA (e-mail: zanderi@ related to the “binding potential” of the radioligand to its target nyspi.columbia.edu). R. Todd Ogden is with the Department of Biostatistics, Columbia University, (i.e., BPP or BPND). While arterial sampling is routinely done New York, NY 10032 USA (e-mail: [email protected]). in research studies, it is invasive, necessitates specific techni- J. J. Mann is with the Department of Psychiatry, Columbia University, New cal expertise, exposes clinical personnel to radiation, involves York, NY 10032 USA (e-mail: [email protected]). R. V. Parsey is with the Department of Psychiatry, Stony Brook University, laboratory analysis costs, significant measurement error, and Stony Brook, NY 11794 USA (e-mail: Ramin.Parsey@stonybrookmedicine. strongly discourages subject participation in PET studies. If the edu). patient refuses an arterial line, or if arterial cannulation or blood Color versions of one or more of the figures in this paper are available online at http://ieeexplore.ieee.org. assay fails, the entire study may be dropped from data analy- Digital Object Identifier 10.1109/JBHI.2015.2416251 sis leaving expensive PET images that cannot be interpreted or 2168-2194 © 2015 IEEE. Translations and content mining are permitted for academic research only. Personal use is also permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications standards/publications/rights/index.html for more information. 1272 IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS, VOL. 19, NO. 4, JULY 2015 analyzed. Even when these challenges are anticipated, it may not ROIs. SIME exploits a parametric model for the unknown AIF always be possible to perform arterial blood sampling, such as and seeks to estimate model parameters simultaneously with the with vulnerable populations (e.g., elderly, cancer patients), those kinetic parameters related to the binding, while fitting several with movement disorders (e.g., people affected by Parkinson’s ROIs at the same time. Recent work has shown that SIME can disease) or in a combined magnetic resonance imaging (MRI) recover the AIF using only a single arterial blood sample as and PET scanner due to magnetic interference. Even when blood an anchor (or constraint) that ensures model identifiability [15]. samples can be obtained, fitting of TP and PF can be challeng- One more alternative for a “less” invasive IDIF is to measure TP ing due to inherent noise present in the blood measurements, and PF from venous blood sampling [3]. Drawing venous blood and complex radioligand kinetics such as “lung trapping” that does not require arterial catheterization by trained personnel, require adapting and validating a metabolite model [2]. Finally, making it more practical in research and clinical settings. For and most commonly, arterial sampling is impractical in a clin- some radioligands, this substitution is nearly equivalent as with ical setting, hindering adoption of quantitative PET outcome [18F]FDG [10], [16] and [11C]WAY [17]. The equivalence be- measures for clinical use. tween arterial and venous blood must be determined separately The last decade has brought a considerable effort to develop for each radioligand and often does not hold. This procedure AIF estimation techniques [3] that can be broadly categorized still requires considerable effort with regards to blood draws as noninvasive (i.e., without blood samples), such as “reference and the metabolite correction assay. tissue” and population-based approaches, and minimally inva- A totally noninvasive AIF estimation approach is needed to sive (i.e., with few blood samples), such as image-derived input overcome the aforesaid challenges and drawbacks with existing functions (IDIF). IDIF techniques. Our proposed solution taps into the field of Reference tissue methods use only imaging data to estimate population pharmacokinetics and pharmacodynamics (PPKD) kinetic parameters of tissue TACs, based on the specification that focuses on predicting metabolite corrected blood levels of that a valid reference region devoid of the target (e.g., receptor pharmaceutical compounds at various time points after injec- or protein of interest) exists and can be identified [4]. This ap- tion. This is done by aggregating blood data from many subjects proach allows estimation of BPND only. For many radioligands to determine what measures (e.g., age, body mass index (BMI), currently employed in brain studies, a reference region truly de- glomerular filtration rate, etc.) explain the variance in drug blood void of the target cannot be identified or the region commonly concentration [18]. Previous work suggests that combining sup- used as a reference actually has measurable specific binding. plementary information (e.g., weight, height, ID) with signal Even when a reference region is identifiable, there may be high from cranial blood vessels improves IDIF-based AIF estimation bias and variance in BPND values calculated with the reference [19]. However, this technique was developed for the radioligand tissue methods when compared to using the AIF, as is the case [18F]FDG for which metabolites are not present in the blood with [11C]-PK11195 (targeting microglia) [5], and [11C]ABP (i.e., PF = 1).
Load more

Recommended publications
  • Test–Retest Variability of Serotonin 5-HT2A Receptor Binding Measured with Positron Emission Tomography and [18F]Altanserin in the Human Brain
    SYNAPSE 30:380–392 (1998) Test–Retest Variability of Serotonin 5-HT2A Receptor Binding Measured With Positron Emission Tomography and [18F]Altanserin in the Human Brain GWENN S. SMITH,1,2* JULIE C. PRICE,2 BRIAN J. LOPRESTI,2 YIYUN HUANG,2 NORMAN SIMPSON,2 DANIEL HOLT,2 N. SCOTT MASON,2 CAROLYN CIDIS MELTZER,1,2 ROBERT A. SWEET,1 THOMAS NICHOLS,2 DONALD SASHIN,2 AND CHESTER A. MATHIS2 1Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 2Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania KEY WORDS positron emission tomography (PET); serotonin receptor; 5-HT2A; imaging ABSTRACT The role of serotonin in CNS function and in many neuropsychiatric diseases (e.g., schizophrenia, affective disorders, degenerative dementias) support the development of a reliable measure of serotonin receptor binding in vivo in human subjects. To this end, the regional distribution and intrasubject test–retest variability of the binding of [18F]altanserin were measured as important steps in the further development of [18F]altanserin as a radiotracer for positron emission tomography (PET) 18 studies of the serotonin 5-HT2A receptor. Two high specific activity [ F]altanserin PET studies were performed in normal control subjects (n ϭ 8) on two separate days (2–16 days apart). Regional specific binding was assessed by distribution volume (DV), estimates that were derived using a conventional four compartment (4C) model, and the Logan graphical analysis method. For both analysis methods, levels of [18F]altanserin binding were highest in cortical areas, lower in the striatum and thalamus, and lowest in the cerebellum.
    [Show full text]
  • Current Status and Growth of Nuclear Theranostics in Singapore
    Nuclear Medicine and Molecular Imaging (2019) 53:96–101 https://doi.org/10.1007/s13139-019-00580-3 PERSPECTIVE ISSN (print) 1869-3482 ISSN (online) 1869-3474 Current Status and Growth of Nuclear Theranostics in Singapore Hian Liang Huang1,2 & Aaron Kian Ti Tong1,2 & Sue Ping Thang1,2 & Sean Xuexian Yan1,2 & Winnie Wing Chuen Lam1,2 & Kelvin Siu Hoong Loke1,2 & Charlene Yu Lin Tang1 & Lenith Tai Jit Cheng1 & Gideon Su Kai Ooi1 & Han Chung Low1 & Butch Maulion Magsombol1 & Wei Ying Tham1,2 & Charles Xian Yang Goh 1,2 & Colin Jingxian Tan 1 & Yiu Ming Khor1,2 & Sumbul Zaheer1,2 & Pushan Bharadwaj1,2 & Wanying Xie1,2 & David Chee Eng Ng1,2 Received: 3 January 2019 /Revised: 13 January 2019 /Accepted: 14 January 2019 /Published online: 25 January 2019 # Korean Society of Nuclear Medicine 2019 Abstract The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
    [Show full text]
  • In Vivo Molecular Imaging: Ligand Development and Research Applications
    31 IN VIVO MOLECULAR IMAGING: LIGAND DEVELOPMENT AND RESEARCH APPLICATIONS MASAHIRO FUMITA AND ROBERT B. INNIS In positron emission tomography (PET) and single-photon ders must be addressed. Physical barriers include limited emission computed tomography (SPECT), tracers labeled anatomic resolution and the need for even higher sensitivity. with radioactive isotopes are used to measure protein mole- However, recent developments with improved detector cules (e.g., receptors, transporters, and enzymes). A major crystals (e.g., lutetium oxyorthosilicate) and three-dimen- advantage of these two radiotracer techniques is extraordi- sional image acquisition have markedly enhanced both sen- -M), many orders sitivity and resolution. (5). Commercially available PET de 12מto 10 9מnarily high sensitivity (ϳ 10 of magnitude greater than the sensitivities available with vices provide resolution of 2 to 2.5 mm (6,7). Furthermore, -M) or mag- the relatively high cost of imaging with SPECT, and espe 4מmagnetic resonance imaging (MRI) (ϳ 10 M). cially PET, can be partially subsidized by clinical use of the 5מto 10 3מnetic resonance spectroscopy (MRS) (ϳ 10 For example, MRI detection of gadolinium occurs at con- devices. Recent approval of U.S. government (i.e., Medi- מ centrations of approximately 10 4 M (1), and MRS mea- care) reimbursement of selected PET studies for patients sures brain levels of ␥-aminobutyric acid (GABA) and gluta- with tumors, epilepsy, and cardiac disease has significantly מ mine at concentrations of approximately 10 3 M (2,3). enhanced the sales of PET cameras and their availability for In contrast, PET studies with [11C]NNC 756 in which a partial use in research studies.
    [Show full text]
  • [18F] Altanserin Bolus Injection in the Canine Brain Using PET Imaging
    Pauwelyn et al. BMC Veterinary Research (2019) 15:415 https://doi.org/10.1186/s12917-019-2165-5 RESEARCH ARTICLE Open Access Kinetic analysis of [18F] altanserin bolus injection in the canine brain using PET imaging Glenn Pauwelyn1*† , Lise Vlerick2†, Robrecht Dockx2,3, Jeroen Verhoeven1, Andre Dobbeleir2,5, Tim Bosmans2, Kathelijne Peremans2, Christian Vanhove4, Ingeborgh Polis2 and Filip De Vos1 Abstract 18 Background: Currently, [ F] altanserin is the most frequently used PET-radioligand for serotonin2A (5-HT2A) receptor imaging in the human brain but has never been validated in dogs. In vivo imaging of this receptor in the canine brain could improve diagnosis and therapy of several behavioural disorders in dogs. Furthermore, since dogs are considered as a valuable animal model for human psychiatric disorders, the ability to image this receptor in dogs could help to increase our understanding of the pathophysiology of these diseases. Therefore, five healthy laboratory beagles underwent a 90-min dynamic PET scan with arterial blood sampling after [18F] altanserin bolus injection. Compartmental modelling using metabolite corrected arterial input functions was compared with reference tissue modelling with the cerebellum as reference region. 18 Results: The distribution of [ F] altanserin in the canine brain corresponded well to the distribution of 5-HT2A receptors in human and rodent studies. The kinetics could be best described by a 2-Tissue compartment (2-TC) model. All reference tissue models were highly correlated with the 2-TC model, indicating compartmental modelling can be replaced by reference tissue models to avoid arterial blood sampling. Conclusions: This study demonstrates that [18F] altanserin PET is a reliable tool to visualize and quantify the 5- HT2A receptor in the canine brain.
    [Show full text]
  • Altanserin and [18F]Deuteroaltanserin for PET
    Nuclear Medicine and Biology 28 (2001) 271–279 Comparison of [18F]altanserin and [18F]deuteroaltanserin for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies Julie K. Staleya,*, Christopher H. Van Dycka, Ping-Zhong Tana, Mohammed Al Tikritia, Quinn Ramsbya, Heide Klumpa, Chin Ngb, Pradeep Gargb, Robert Souferb, Ronald M. Baldwina, Robert B. Innisa,c aDepartment of Psychiatry, Yale University School of Medicine and VA Connecticut Healthcare System, West Haven, CT 06516, USA bDepartment of Radiology, Yale University School of Medicine and VA Connecticut Healthcare System, West Haven, CT 06516, USA cDepartment of Pharmacology, Yale University School of Medicine and VA Connecticut Healthcare System, West Haven, CT 06516, USA Received 2 September 2000; received in revised form 30 September 2000; accepted 18 November 2000 Abstract The regional distribution in brain, distribution volumes, and pharmacological specificity of the PET 5-HT2A receptor radiotracer [18F]deuteroaltanserin were evaluated and compared to those of its non-deuterated derivative [18F]altanserin. Both radiotracers were administered to baboons by bolus plus constant infusion and PET images were acquired up to 8 h. The time-activity curves for both tracers stabilized between 4 and 6 h. The ratio of total and free parent to metabolites was not significantly different between radiotracers; nevertheless, total cortical RT (equilibrium ratio of specific to nondisplaceable brain uptake) was significantly higher (34–78%) for 18 18 18 [ F]deuteroaltanserin than for [ F]altanserin. In contrast, the binding potential (Bmax/KD) was similar between radiotracers. [ F]Deu- teroaltanserin cortical activity was displaced by the 5-HT2A receptor antagonist SR 46349B but was not altered by changes in endogenous 18 18 5-HT induced by fenfluramine.
    [Show full text]
  • Tracking Down the Antimigraine Effect of Triptans; the Relationship Between 5-HT1B Receptors in the Vasculature and Parenchyma Mentor 1 Gitte Moos Knudsen
    U NIVERSITY OF COPENHAGEN FACULTY OF HEALTH AND MEDICAL SCIENCES BRIDGE- TRANSLATIONAL EXCELLENCE PROGRAMME PROJECT SYNOPSIS TEMPLATE 1 Project title Tracking down the antimigraine effect of triptans; The relationship between 5-HT1B receptors in the vasculature and parenchyma Mentor 1 Gitte Moos Knudsen. Professor, Neurobiology Research Unit (NRU), Rigshospitalet ([email protected]) Mentor 2 Birger Brodin. Professor, Department of Pharmacy, UCPH ([email protected]) Framework The selected candidate will work in a translational environment, where competences ranging from molecular biology to in vivo imaging are used to address a major health problem; the origin of migraine and the effect and site of action of antimigraine compounds. The project will carried out in a collaboration between the labs of Gitte Moos Knudsen and Birger Brodin. The lab of Gitte Moos Knudsen represents “state of the art” within in vivo radioligand imaging and receptors characterization. Birger Brodin’s lab specializes in in vitro characterization of brain microvasculature, including expression of receptors and transporters and basic capillary biology. Both groups have strong national and international networks, strong traditions for collaborative research projects and are well recognized in their fields, securing a good collaborative working environment and a solid network for the selected candidate. Project The serotonin 1B receptors (5-HT1BR) are involved in several psychophysiological synopsis functions and disorders: locomotor activity, depression, anxiety states, and aggressive-like behaviour. Therapeutically, the 5-HT1BR constitutes an important target in migraine intervention, where headache is alleviated by administration of triptans that mediate an agonist action on the 5-HT1B/1D/1F receptors resulting in vasoconstriction of the vessels.
    [Show full text]
  • A Picture of Modern Tc-99M Radiopharmaceuticals: Production, Chemistry, and Applications in Molecular Imaging
    applied sciences Review A Picture of Modern Tc-99m Radiopharmaceuticals: Production, Chemistry, and Applications in Molecular Imaging Alessandra Boschi 1 , Licia Uccelli 2,3 and Petra Martini 2,4,* 1 Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Via Luigi Borsari, 46, 44121 Ferrara, Italy; [email protected] 2 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari, 46, 44121 Ferrara, Italy; [email protected] 3 Nuclear Medicine Unit, University Hospital, Via Aldo Moro, 8, 44124 Ferrara, Italy 4 Legnaro National Laboratories, Italian National Institute for Nuclear Physics (LNL-INFN), Viale dell’Università, 2, 35020 Legnaro (PD), Italy * Correspondence: [email protected]; Tel.: +39-0532-455354 Received: 15 May 2019; Accepted: 19 June 2019; Published: 21 June 2019 Abstract: Even today, techentium-99m represents the radionuclide of choice for diagnostic radio-imaging applications. Its peculiar physical and chemical properties make it particularly suitable for medical imaging. By the use of molecular probes and perfusion radiotracers, it provides rapid and non-invasive evaluation of the function, physiology, and/or pathology of organs. The versatile chemistry of technetium-99m, due to its multi-oxidation states, and, consequently, the ability to produce a variety of complexes with particular desired characteristics, are the major advantages of this medical radionuclide. The advances in technetium coordination chemistry over the last 20 years, in combination with recent advances in detector technologies and reconstruction algorithms, make SPECT’s spatial resolution comparable to that of PET, allowing 99mTc radiopharmaceuticals to have an important role in nuclear medicine and to be particularly suitable for molecular imaging.
    [Show full text]
  • PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives
    molecules Review PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives Santosh Reddy Alluri 1 , Sung Won Kim 2, Nora D. Volkow 2,3,* and Kun-Eek Kil 1,4,* 1 University of Missouri Research Reactor, University of Missouri, Columbia, MO 65211-5110, USA; [email protected] 2 Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892-1013, USA; [email protected] 3 National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892-1013, USA 4 Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO 65211, USA * Correspondence: [email protected] (N.D.V.); [email protected] (K.-E.K.); Tel.: +1-(301)-443-6480 (N.D.V.); +1-(573)-884-7885 (K.-E.K.) Academic Editor: Krishan Kumar Received: 31 July 2020; Accepted: 1 September 2020; Published: 3 September 2020 Abstract: Epinephrine (E) and norepinephrine (NE) play diverse roles in our body’s physiology. In addition to their role in the peripheral nervous system (PNS), E/NE systems including their receptors are critical to the central nervous system (CNS) and to mental health. Various antipsychotics, antidepressants, and psychostimulants exert their influence partially through different subtypes of adrenergic receptors (ARs). Despite the potential of pharmacological applications and long history of research related to E/NE systems, research efforts to identify the roles of ARs in the human brain taking advantage of imaging have been limited by the lack of subtype specific ligands for ARs and brain penetrability issues. This review provides an overview of the development of positron emission tomography (PET) radiotracers for in vivo imaging of AR system in the brain.
    [Show full text]
  • Trends in Radiopharmaceuticals
    ISTR–2019 International Symposium on Trends in Radiopharmaceuticals 28 October–1 November 2019 Vienna, Austria Programme & Abstracts ISTR–2019 Organized by Colophon This book has been assembled from the abstract sources submitted by the contributing authors via the Indico conference management platform. Layout, editing, and typesetting of the book, was done by Ms. Julia S. Vera Araujo from the Radioisotope Products and Radiation Technology section, IAEA, Vienna, Austria. This book is PDF hyperlinked: activating coloured text will, in general, move you throughout the book, or link to external resources on the web. ISTR–2019 INTRODUCTION Progress in nuclear medicine has been always tightly linked to the development of new radiopharmaceuticals and efficient production of relevant radioisotopes. The use of radiopharmaceuticals is an important tool for better understanding of human diseases and developing effective treatments. The availability of new radioisotopes and radiopharmaceuticals may generate unprecedented solutions to clinical problems by providing better diagnosis and more efficient therapies. Impressive progress has been made recently in the radioisotope production technologies owing to the introduction of high-energy and high-current cyclotrons and the growing interest in the use of linear accelerators for radioisotope production. This has allowed broader access to several new radionuclides, including gallium-68, copper-64 and zirconium-89. Development of high-power electron linacs resulted in availability of theranostic beta emitters such as scandium-47 and copper-67. Alternative, accelerator-based production methods of technetium-99m, which remains the most widely used diagnostic radionuclide, are also being developed using both electron and proton accelerators. Special attention has been recently given to α-emitting radionuclides for in-vivo therapy.
    [Show full text]
  • Evaluation of the Superselective Radioligand [ I]PE2I for Imaging of the Dopamine Transporter in SPECT
    PHD THESIS DANISH MEDICAL BULLETIN Evaluation of the superselective radioligand [ 123 I]PE2I for imaging of the dopamine transporter in SPECT. Morten Ziebell (DA) [1]. DA was synthesised in 1910 by George Barger and colleagues [2]. They found it to be a weak sympathomimetic compound and so it was left unexplored for more than three This review has been accepted as a thesis together with four previously published papers by University of Copenhagen 20th of January 2011 and defended on 18th of decades. What Arvid Carlsson found out years later, was that March 2011. dopamine was a neurotransmitter by itself and not only a precursor for norepinephrine and epinephrine. In the same Tutor: Gitte Moos Knudsen period the enzyme aromatic-L-amino-acid decarboxylase (also Official opponents: Lars Friberg, Jan Booij, Anna M. Catafau. called dopa decarboxylase or AAAD) was discovery by a German scientist [3]. The discovery of this enzyme, which in mammalian Correspondence: Department of Neurology, Neurobiology Research Unit, tissues converts 3,4-dihydroxyphenylalanine (L-DOPA) to Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen. Denmark dopamine, provided a mechanism for the formation of dopamine in the brain because unlike dopamine itself, L-DOPA can cross the E-mail: [email protected] blood brain barrier (BBB). Since then the neurotransmitter dopamine has been the subject of enormous scientific interest; mentioned in almost 65.000 papers when combined with search Dan Med Bull 2011;58(5): B4279 term “brain” in a Pubmed search in September 2010. DA neurons play a key role in many basic functions of the brain, THE 4 ORIGINAL PAPERS ARE such as motivation, motor behaviour and working memory.
    [Show full text]
  • Wx Reduced Binding of F Altanserin to Serotonin Type 2A Receptors in Aging
    Brain Research 813Ž. 1998 167±171 Short communication Reduced binding ofw18 Fx altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction Carolyn Cidis Meltzer a,b,), Gwenn Smith a,b, Julie C. Price a, Charles F. Reynolds III b,c, Chester A. Mathis a,d, Phil Greer a, Brian Lopresti a, Mark A. Mintun a,b, Bruce G. Pollock b, Doron Ben-Eliezer a, Michael N. Cantwell a, Walter Kaye b, Steven T. DeKosky b,c a Department of Radiology, UniÕersity of Pittsburgh, Pittsburgh, PA 15213, USA b Department of Psychiatry, UniÕersity of Pittsburgh, Pittsburgh, PA 15213, USA c Department of Neurology, UniÕersity of Pittsburgh, Pittsburgh, PA 15213, USA d Department of Pharmaceutical Sciences, UniÕersity of Pittsburgh, Pittsburgh, PA 15213, USA Accepted 25 August 1998 Abstract The serotoninŽ. 5-HT neurotransmitter system, which has a widespread distribution in the central nervous system, has been implicated in regulating mood and many human behaviors. There is evidence from postmortem human studies and limited information from prior in vivo studies to support a decline in 5-HT2A receptor density with aging. We examined nine elderlyŽ. ages 61±76 and nine young Ž ages 18±29.Ž. healthy individuals with positron emission tomography PET andw18 Fx altanserin, a ligand with high affinity for the 5-HT2A binding site. The PET data were corrected for differences in brain tissue volume between the young and elderly subjects using a magnetic resonanceŽ. MR imaging-based partial volume correction method. Highly significant and widespread cortical reductions in 5-HT2A specific binding were demonstrated in the elderly group relative to young controls.
    [Show full text]
  • A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 30 November 2020 doi:10.20944/preprints202011.0742.v1 Type of the Paper: Article A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain Nakul Ravi Raval1,2, Annette Johansen1,2, Lene Lundgaard Donovan1,2, Nidia Fernandez Ros1, Brice Ozenne1,3, Hanne Demant Hansen1,4, Gitte Moos Knudsen1,2,* 1 Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 2 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3 Department of Public Health, Section of Biostatistics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 4 A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, MA, USA * Correspondence: Gitte Moos Knudsen (email: [email protected]) Abstract: A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5- HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and 5-HT2AR density in the pig brain. Twenty-four awake pigs received either 0.08 mg/kg psilocybin or saline intravenously. Twelve pigs (n=6/intervention) were euthanized one day post-injection, while the remaining twelve pigs were euthanized seven days post-injection (n=6/intervention). We performed autoradiography on hippocampus and prefrontal cortex (PFC) sections with [3H]UCB-J (SV2A), [3H]MDL100907 (5-HT2AR antagonist) and [3H]Cimbi-36 (5-HT2AR agonist).
    [Show full text]